This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area

Beyonttra
®
▼(acoramidis)

All-cause mortality in the open-label extension

Beyonttra - Patient Image

Continuous Beyonttra® significantly prevented death compared to the placebo-to-Beyonttra arm at Month 42

  • Participants who completed the 30-month ATTRibute-CM study were invited to participate in the OLE study.
  • Participants who previously received acoramidis continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis).
  • All participants received BEYONTTRA® 800 mg BID.

Time to ACM from baseline through month 42 in the OLE study

Kaplan-Meier-curve-for-time-to-ACM---Graph & Highlight
Kaplan-Meier-curve-for-time-to-ACM---Graph & Highlight
Beyonttra®▼ (acoramidis) - Post-hoc Analysis of serum TTR
Learn more about the Efficacy: Post-hoc Analysis of serum transthyretin (TTR) of Beyonttra® (acoramidis).
PP-BEY-IE-0042-1, November 2025
Beyonttra®▼ (acoramidis) - Safety Profile
Learn more about the Safety Profile of Beyonttra® (acoramidis).
PP-BEY-IE-0033-1, November 2025
Beyonttra®▼ (acoramidis) - Dosing
Learn more about the Dosing of Beyonttra® (acoramidis).
PP-BEY-IE-0032-1, November 2025

Abbreviations:
 

ACM
, all-cause mortality;
ARR
, absolute risk reduction;
CI
, confidence interval;
RRR
, relative risk reduction.

 

PP-BEY-IE-0037-1   |   November 2025

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.